Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
Mallinckrodt
Baxter
QuintilesIMS
Dow
McKinsey
Queensland Health
Citi

Generated: May 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,753,677

« Back to Dashboard

Which drugs does patent 5,753,677 protect, and when does it expire?

Patent 5,753,677 protects SAMSCA and is included in one NDA.

This patent has twenty patent family members in thirteen countries.
Summary for Patent: 5,753,677
Title: Benzoheterocyclic compounds
Abstract:Novel benzoheterocyclic compounds of the formula: ##STR1## which have excellent vasopressin antagonistic activities and are useful as vasodilator, hypotensive agent, water diuretics, platelet agglutination inhibitor, and a vasopressin antagonistic composition containing the compound as the active ingredient.
Inventor(s): Ogawa; Hidenori (Tokushima-ken, JP), Miyamoto; Hisashi (Kyoto-fu, JP), Kondo; Kazumi (Tokushima-ken, JP), Yamashita; Hiroshi (Tokushima-ken, JP), Nakaya; Kenji (Tokushima-ken, JP), Komatsu; Hajime (Tokushima-ken, JP), Tanaka; Michinori (Tokushima-ken, JP), Kora; Shinya (Nagasaki-ken, JP), Tominaga; Michiaki (Tokushima-ken, JP), Yabuuchi; Yoichi (Tokushima-ken, JP)
Assignee: Otsuka Pharmaceutical Co., Ltd. (Tokyo, JP)
Application Number:08/474,544
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 5,753,677
Patent Claim Types:
see list of patent claims
Use; Compound;

Drugs Protected by US Patent 5,753,677

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Otsuka America Pharm SAMSCA tolvaptan TABLET;ORAL 022275-001 May 19, 2009 RX Yes No ➤ Sign Up ➤ Sign Up METHOD OF TREATING HYPONATREMIA ➤ Sign Up
Otsuka America Pharm SAMSCA tolvaptan TABLET;ORAL 022275-002 May 19, 2009 RX Yes Yes ➤ Sign Up ➤ Sign Up METHOD OF TREATING HYPONATREMIA ➤ Sign Up
Otsuka America Pharm SAMSCA tolvaptan TABLET;ORAL 022275-003 May 19, 2009 DISCN Yes No ➤ Sign Up ➤ Sign Up METHOD OF TREATING HYPONATREMIA ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 5,753,677

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,985,869 Benzoheterocyclic compounds ➤ Sign Up
5,258,510 United States Patent: 5258510   ( 1 ➤ Sign Up
5,559,230 Benzoheterocyclic compounds ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Mallinckrodt
Chubb
Daiichi Sankyo
US Department of Justice
Teva
Merck
Federal Trade Commission
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.